Improved survival with bisoprolol in patients with heart failure and renal impairment: an analysis of the cardiac insufficiency bisoprolol study II (CIBIS‐II) trial

  title={Improved survival with bisoprolol in patients with heart failure and renal impairment: an analysis of the cardiac insufficiency bisoprolol study II (CIBIS‐II) trial},
  author={Davide Castagno and Pardeep S. Jhund and John J. V. McMurray and James Lewsey and Erland Erdmann and Faiez Zannad and Willem J. Remme and Jos{\'e} Luis L{\'o}pez-Send{\'o}n and Philippe P Lechat and Ferenc Follath and Christer H{\"o}glund and V. Yu. Mareev and Zygmunt P Sadowski and Ricardo J. Seabra-Gomes and Henry J. Dargie},
  journal={European Journal of Heart Failure},
Information on the effectiveness of beta‐blockade in patients with heart failure (HF) and concomitant renal impairment is scarce and beta‐blockers are underutilized in these patients. 
Cardiorenal syndrome: Pathophysiology, preclinical models, management and potential role of uraemic toxins
1. Cardiorenal syndrome (CRS) describes the primary dysfunction in either the kidney or heart that initiates the combined impairment of both organs. The heart and kidney exert reciprocal control of
Impact of Renal Impairment on Beta-Blocker Efficacy in Patients With Heart Failure.
The Acute Cardiorenal Syndrome: Burden and Mechanisms of Disease
Emerging data support therapeutic strategies that permit WRF while effectively treating congestion as they are associated with improved outcomes.
(Pharmacotherapy of chronic heart failure from the viewpoint of the new ESC 2021 guidelines)
A brief summary of the pharmacotherapy of chronic heart failure as it was published in the new 2021 guidelines of the European Society of Cardiology is offered.
Evidence-Based Medical Therapy in Patients With Heart Failure With Reduced Ejection Fraction and Chronic Kidney Disease
It is shown that for both all-cause mortality and the combined end point of cardiovascular death or heart failure hospitalization, most drug classes are safe and effective up to CKD stage 3B, and a decline in eGFR in the context of a stable or improving clinical condition should not be cause for concern and should not lead to discontinuation of life-saving HFrEF therapies.
Management of Heart Failure in Patients with Chronic Kidney Disease
Interdisciplinary input from HF and renal specialists is required to provide integrated care for the growing number of patients with HF and CKD.
We should not hesitate to use beta-blockers for systolic heart failure with concomitant renal dysfunction.
  • N. Matsuda
  • Medicine
    Circulation journal : official journal of the Japanese Circulation Society
  • 2010
Fear of adverse potential and limited information about long-term effects and tolerability might explain the clinical hesitation to administer β-blockers for heart failure and concomitant chronic kidney disease.
University of Groningen Impact of Renal Impairment on Beta-Blocker Efficacy in Patients With Heart Failure Beta-Blockers Heart Failure
Patients with heart failure, left ventricular ejection fraction <50% and sinus rhythm should receive beta-blocker therapy even with moderate or moderately severe renal dysfunction, according to renal function using estimated glomerular filtration rate (eGFR).
Renal effects of guideline‐directed medical therapies in heart failure: a consensus document from the Heart Failure Association of the European Society of Cardiology
Advice is provided of the effect HF drugs on renal function as the emerge of several new classes and the recommendation by the 2021 ESC guidelines of early initiation and titration of quadruple disease‐modifying therapies in HFrEF increases the likelihood of treatment‐induced changes in renal function.


Efficacy and safety of nebivolol in elderly heart failure patients with impaired renal function: insights from the SENIORS trial
To determine the safety and efficacy of nebivolol in elderly heart failure (HF) patients with renal dysfunction, a large number of patients with kidney dysfunction are treated with this drug.
Design of the cardiac insufficiency bisoprolol study II (CIBIS II). The CIBIS II Scientific Committee.
  • Medicine
    Fundamental & clinical pharmacology
  • 1997
The objective of the Cardiac Insufficiency Bisoprolol Study II (CIBIS II) is to evaluate effects of the selective beta-1 adrenoceptor blocker, bisoproll, on mortality (primary endpoint) in patients with ischaemic or non-ischaemic chronic heart failure.
beta-Blocker use in long-term dialysis patients: association with hospitalized heart failure and mortality.
In dialysis patients without a previous documented history of heart failure, beta-blocker use was associated with a lower risk of new HF, cardiovascular death, and death from any cause, and no such associations were seen for Dialysis patients with a previous history of HF.
Renal function, neurohormonal activation, and survival in patients with chronic heart failure.
Impaired renal function (GFR(c)) is a stronger predictor of mortality than impaired cardiac function (LVEF and New York Heart Association class) in advanced CHF, and it is associated with increased levels of N-terminal ANP.
Renal Insufficiency and Heart Failure: Prognostic and Therapeutic Implications From a Prospective Cohort Study
Renal insufficiency is more prevalent in patients with heart failure than previously reported and is an independent prognostic factor in diastolic and systolic dysfunction.